Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
批准号:
7736328
负责人:
ELAINE R. PESKIND
金额:
$49.47万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-15 至 2012-07-31
关键词:
Activities of Daily LivingAdrenergic AntagonistsAdrenergic ReceptorAdverse effectsAdverse eventAgitationAlzheimer&aposs DiseaseAntipsychotic AgentsAnxietyAreaArousalAutopsyBasic ScienceBehaviorBehavioralBoxingBrainBrief Psychiatric Rating ScaleCaregiver BurdenCaregiversCerebrospinal FluidCessation of lifeChronicClinicClinicalClinical ResearchClinical TrialsControlled Clinical TrialsDataDementiaDevelopmentDiseaseDistressDoseDouble-Blind MethodDropoutElderlyEnvironmentEpinephrineEquipment and supply inventoriesEventFeasibility StudiesFrail ElderlyFunctional disorderFutureGeneric DrugsGoalsHome environmentImpaired cognitionLinear ModelsLong-Term CareLong-Term Care NursingLorazepamMaintenanceMethodsNeuraxisNeuronsNorepinephrineNursing HomesOutcome MeasureOutpatientsPatientsPersonsPharmaceutical PreparationsPhasePilot ProjectsPlacebo ControlPlacebosPopulationPrazosinProcessProsencephalonRandomizedRiskSafetySourceStressStrokeSumSymptomsSyndromeTestingTherapeuticTherapeutic EffectTimeTranslatingUp-Regulationatypical antipsychoticbrain tissuecaregivingcerebrovascularclinical practicecooperative studydensitydesigndiscontinuation trialimpressionmental stateneuropsychiatrynoradrenergicopen labelpilot trialplacebo controlled studyprimary outcomepsychopharmacologicpublic health relevanceresponsesecondary outcomesurvivorship
中文摘要
描述(由申请人提供):在大多数阿尔茨海默病(AD)患者的病程中,破坏性激越是一种令人痛苦且经常持续的行为。它大大增加了家庭和长期护理环境中护理人员的负担,是疗养院安置的主要因素,并导致患者遭受痛苦、护理环境中的压力和负担增加。破坏性激越可能是AD和相关痴呆患者广泛使用精神药物处方的最重要原因。在精神药物中,只有抗精神病药物一直被证明上级安慰剂对这些痛苦的症状。然而,在多项非典型抗精神病药物的大型临床试验中,效应大小适中,无应答者频繁,不良反应常见,死亡和脑血管不良事件的风险增加,这促使FDA对痴呆症患者使用这些药物发出“黑盒警告”。很明显,寻找新的药理学方法来减少AD的破坏性激越是一个重要的临床目标。本申请提出了一项安慰剂对照的初步试验,一般可用的脑活性α-1肾上腺素受体(AR)拮抗剂,哌唑嗪,在AD的破坏性激越。AD患者和AD脑组织的临床研究表明,中枢神经系统(CNS)α-1 AR对去甲肾上腺素(NE)的反应性增强有助于AD的破坏性激越。来自一项开放标签试验和一项小型安慰剂对照可行性试验的强阳性初步数据支持哌唑嗪在患有严重破坏性激越的AD患者中的潜在疗效和良好耐受性。我们将128例AD患者随机分为哌唑嗪组(最大剂量4 mg b.i.d.)或安慰剂进行为期12周的双盲试验。试验期间维持药物将保持不变。主要结果测量是阿尔茨海默病合作研究(ADCS)临床总体印象变化和神经精神量表总分。次要结果测量是简明精神病评定量表(BPRS)总评分、BPRS激越因子、ADCS-Activities of Daily Living-19和简易精神状态检查。将检验以下假设:1a)随机分配至哌唑嗪组的AD患者比随机分配至安慰剂组的AD患者具有更大的破坏性激越行为减少; 1b)哌唑嗪组“补救”劳拉西泮的总剂量低于安慰剂组受试者; 1c)至研究中止的时间哌唑嗪组由于持续激越导致的脱落率(“脱落”)高于安慰剂组;和1d)哌唑嗪组和安慰剂组之间因不良反应而中止研究(“脱落”)的时间没有差异。在12周安慰剂对照期结束时,所有受试者将额外接受12周的开放标签哌唑嗪治疗,以收集哌唑嗪对破坏性激越的预测治疗效果弹性的观察数据。如果这项初步研究的结果是积极的,我们将通过阿尔茨海默病合作研究机制进行一项大型的确定性多中心研究。公共卫生相关性:阿尔茨海默病(AD)的破坏性激越发生在大多数患者的病程中。这种综合征是患者和护理人员痛苦和疗养院安置的主要来源,目前的治疗方法往往是不够的。本申请提出了一项安慰剂对照试验的仿制药哌唑嗪破坏性激越在AD。哌唑嗪可阻断导致AD患者激越的脑肾上腺素过度兴奋,我们的哌唑嗪可行性研究的治疗和耐受性结果非常有希望。
英文摘要
DESCRIPTION (provided by applicant): Disruptive agitation emerges as a distressing and often persistent group of behaviors during the disease course of the majority of persons with Alzheimer's disease (AD). It greatly increases caregiver burden in both the home and long-term care settings, is a leading precipitant of nursing home placement, and causes suffering in patients and stress and increased burden in the caregiving environment. Disruptive agitation is likely the most important reason for the widespread prescription of psychotropic medications in AD and related dementias. Among the psychotropics, only the antipsychotics have been consistently demonstrated superior to placebo for these distressing symptoms. However, effect sizes are modest, nonresponders frequent, adverse effects common, and an increased risk for death and cerebrovascular adverse events in multiple large clinical trials of atypical antipsychotics prompted a "black box warning" from the FDA re: their use in persons with dementia. It is clear that finding new pharmacologic approaches to reducing disruptive agitation in AD is an important clinical goal. This application proposes a placebo-controlled pilot trial of the generically available brain active alpha-1 adrenoreceptor (AR) antagonist, prazosin, for disruptive agitation in AD. Clinical studies in AD patients and AD brain tissue suggest that enhanced responsiveness to norepinephrine (NE) at central nervous system (CNS) alpha-1 ARs contributes to disruptive agitation in AD. Strongly positive preliminary data from an open label trial and a small placebo-controlled feasibility trial of prazosin in AD patients with severe disruptive agitation support potential efficacy and good tolerability in this frail elderly population. We will randomize 128 AD patients with persistent disruptive agitation to prazosin (maximum dose 4 mg b.i.d.) or placebo in a 12-week double-blind trial. Maintenance medications will be kept constant during the trial. Primary outcome measures are the Alzheimer's Disease Cooperative Study (ADCS) Clinical Global Impression of Change and the Neuropsychiatric Inventory total score. Secondary outcome measures are the Brief Psychiatric Rating Scale (BPRS) total score, BPRS Agitation Factor, ADCS-Activities of Daily Living-19, and the Mini Mental State Exam. The following hypotheses will be tested: 1a) AD patients randomized to prazosin will have a greater reduction in disruptive agitated behaviors than those randomized to placebo; 1b) total dose of "rescue" lorazepam will be lower in prazosin than placebo subjects; 1c) time to study discontinuation ("dropout") due to continued agitation will be greater in prazosin than placebo groups; and 1d) time to study discontinuation ("dropout") due to adverse effects will not differ between prazosin and placebo groups. At the completion of the 12-week placebo-controlled phase, all subjects will receive an additional 12 weeks of open label prazosin to gather observational data on the resiliency of the predicted therapeutic effect of prazosin for disruptive agitation. If results of this pilot study are positive, we will pursue a large definitive multisite study through the Alzheimer's Disease Cooperative Study mechanism. PUBLIC HEALTH RELEVANCE: Disruptive agitation in Alzheimer's disease (AD) occurs in the majority of patients over the course of their illness. This syndrome is a major source of patient and caregiver distress and nursing home placement, and current treatment approaches often are inadequate. This application proposes a placebo-controlled trial of the generic drug prazosin for disruptive agitation in AD. Prazosin blocks the excessive brain adrenaline arousal that contributes to agitation in AD and both therapeutic and tolerability results of our prazosin feasibility study are very promising.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the Role of Post-TBI Sleep Disruption in the Development of CTE and Alzheimer's Disease-Related Neuropathology
-
批准号:10523939
-
项目类别:
-
资助金额:$385.99万
-
财政年份:2022
-
负责人:ELAINE R. PESKIND
-
依托单位:
Mild TBI and Biomarkers of Neurodegeneration
-
批准号:10490311
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:ELAINE R. PESKIND
-
依托单位:
Mild TBI and Biomarkers of Neurodegeneration
-
批准号:10269890
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:ELAINE R. PESKIND
-
依托单位:
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease
-
批准号:9265401
-
项目类别:
-
资助金额:$33.25万
-
财政年份:2016
-
负责人:ELAINE R. PESKIND
-
依托单位:
Mild TBI and Biomarkers of Neurodegeneration
-
批准号:8864865
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:ELAINE R. PESKIND
-
依托单位:
Multimodal Biological Assessment of Gulf War Illness
-
批准号:9278098
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:ELAINE R. PESKIND
-
依托单位:
Multimodal Biological Assessment of Gulf War Illness
-
批准号:8967215
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:ELAINE R. PESKIND
-
依托单位:
Multimodal Biological Assessment of Gulf War Illness
-
批准号:8660563
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:ELAINE R. PESKIND
-
依托单位:
Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI
-
批准号:8485152
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:ELAINE R. PESKIND
-
依托单位:
Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI
-
批准号:8990876
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:ELAINE R. PESKIND
-
依托单位:
Mild TBI and Biomarkers of Neurodegeneration
-
批准号:8256521
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:ELAINE R. PESKIND
-
依托单位:
Mild TBI and Biomarkers of Neurodegeneration
-
批准号:8928103
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:ELAINE R. PESKIND
-
依托单位:
Mild TBI and Biomarkers of Neurodegeneration
-
批准号:8088503
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:ELAINE R. PESKIND
-
依托单位:
Mild TBI and Biomarkers of Neurodegeneration
-
批准号:8838166
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:ELAINE R. PESKIND
-
依托单位:
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
-
批准号:7910425
-
项目类别:
-
资助金额:$49.35万
-
财政年份:2009
-
负责人:ELAINE R. PESKIND
-
依托单位:
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
-
批准号:8111821
-
项目类别:
-
资助金额:$47.68万
-
财政年份:2009
-
负责人:ELAINE R. PESKIND
-
依托单位:
CORE--CLINICAL
-
批准号:6932654
-
项目类别:
-
资助金额:$47.38万
-
财政年份:2005
-
负责人:ELAINE R. PESKIND
-
依托单位:
CORE--CLINICAL
-
批准号:6455077
-
项目类别:
-
资助金额:$0.45万
-
财政年份:2001
-
负责人:ELAINE R. PESKIND
-
依托单位:
CORE--CLINICAL
-
批准号:6359533
-
项目类别:
-
资助金额:$0.45万
-
财政年份:2000
-
负责人:ELAINE R. PESKIND
-
依托单位:
ALZHEIMER'S IN LONG TERM PROPRANOLOL FOR AGITATION
-
批准号:6372533
-
项目类别:
-
资助金额:$31.11万
-
财政年份:2000
-
负责人:ELAINE R. PESKIND
-
依托单位:
海外基金